Market Summary

Introduction

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Immunotherapy in Oncology Market Overview: 8 Major Markets 

    3.1    Immunotherapy in Oncology Market Historical Value (2017-2023) 
    3.2    Immunotherapy in Oncology Market Forecast Value (2024-2032)
4    Vendor Positioning Analysis
    4.1    Key Vendors
    4.2    Prospective Leaders
    4.3    Niche Leaders
    4.4    Disruptors
5    Immunotherapy in Oncology: Disease Overview 
    5.1    Guidelines and Stages
    5.2    Pathophysiology
    5.3    Screening and Diagnosis
    5.4    Therapy Pathway 
6    Patient Profile
    6.1    Patient Profile Overview
    6.2    Patient Psychology and Emotional Impact Factors
    6.3    Risk Assessment and Therapy Success Rate
7    Immunotherapy in Oncology Market Epidemiology Scenario and Forecast – 8 Major Markets
    7.1    8MM Epidemiology Scenario Overview (2017-2032)
        7.1.1    Prevalence, by Country
            7.1.1.1    United States
            7.1.1.2    United Kingdom
            7.1.1.3    EU4
            7.1.1.4    India 
            7.1.1.5    Japan
        7.1.2    Mortality by Country
            7.1.2.1    United States
            7.1.2.2    United Kingdom
            7.1.2.3    EU4
            7.1.2.4    India 
            7.1.2.5    Japan
        7.1.3    Treatment Seeking Rate by Country
            7.1.3.1    United States
            7.1.3.2    United Kingdom
            7.1.3.3    EU4
            7.1.3.4    India 
            7.1.3.5    Japan
8    Immunotherapy in Oncology Market Landscape: 8 Major Markets*
    8.1    Immunotherapy in Oncology Market: Developers Landscape
        8.1.1    Analysis by Year of Establishment
        8.1.2    Analysis by Company Size
        8.1.3    Analysis by Region
    8.2    Immunotherapy in Oncology Market: Product Landscape 
        8.2.1    Analysis by Type
        8.2.2    Analysis by Indication
        8.2.3    Analysis by Route of Administration
9    Immunotherapy in Oncology Market Challenges and Unmet Needs
    9.1    Therapy Pathway Challenges
    9.2    Compliance and Drop-Out Analysis
    9.3    Awareness and Prevention Gaps
10    Cost of Treatment    
11    Immunotherapy in Oncology Market Dynamics

    11.1    Market Drivers and Constraints
    11.2    SWOT Analysis
        11.2.1    Strengths
        11.2.2    Weaknesses
        11.2.3    Opportunities
        11.2.4    Threats
    11.3    PESTEL Analysis 
        11.3.1    Political 
        11.3.2    Economic 
        11.3.3    Social 
        11.3.4    Technological 
        11.3.5    Legal 
        11.3.6    Environment
    11.4    Porter’s Five Forces Model
        11.4.1    Bargaining Power of Suppliers
        11.4.2    Bargaining Power of Buyers
        11.4.3    Threat of New Entrants
        11.4.4    Threat of Substitutes
        11.4.5    Degree of Rivalry
    11.5    Key Demand Indicators 
    11.6    Key Price Indicators
    11.7    Industry Events, Initiatives, and Trends 
    11.8    Value Chain Analysis
12    Immunotherapy in Oncology Market (2017-2032) Segmentation: 8 Major Markets
    12.1    Immunotherapy in Oncology Market (2017-2032) by Type
        12.1.1    Market Overview
        12.1.2    Monoclonal Antibodies
        12.1.3    Cytokines & Immunomodulators
        12.1.4    Checkpoint Inhibitors
        12.1.5    Others
    12.2    Immunotherapy in Oncology Market (2017-2032) by Indication
        12.2.1    Market Overview
        12.2.2    Prostate Cancer
        12.2.3    Melanoma
        12.2.4    Head & Neck Cancer
        12.2.5    Breast Cancer
        12.2.6    Colorectal Cancer
        12.2.7    Lung Cancer
        12.2.8    Others
    12.3    Immunotherapy in Oncology Market (2017-2032) by Route of Administration
        12.3.1    Market Overview
        12.3.2    Oral
        12.3.3    Parenteral
    12.4    Immunotherapy in Oncology Market (2017-2032) by End User
        12.4.1    Market Overview
        12.4.2    Hospitals
        12.4.3    Clinics
        12.4.4    Oncology Centers
        12.4.5    Others
    12.5    Immunotherapy in Oncology Market (2017-2032) by Region
        12.5.1    Market Overview
        12.5.2    United States
        12.5.3    EU-4 and the United Kingdom
            12.5.3.1    Germany
            12.5.3.2    France
            12.5.3.3    Italy
            12.5.3.4    Spain
            12.5.3.5    United Kingdom
        12.5.4    Japan
        12.5.5    India
13    United States Immunotherapy in Oncology Market (2017-2032)
    13.1    United States Immunotherapy in Oncology Market Historical Value (2017-2023) 
    13.2    United States Immunotherapy in Oncology Market Forecast Value (2024-2032)
    13.3    United States Immunotherapy in Oncology Market (2017-2032) by Type
        13.3.1    Market Overview
        13.3.2    Monoclonal Antibodies
        13.3.3    Cytokines & Immunomodulators
        13.3.4    Checkpoint Inhibitors
        13.3.5    Others
    13.4    United States Immunotherapy in Oncology Market (2017-2032) by Indication
        13.4.1    Market Overview
        13.4.2    Prostate Cancer
        13.4.3    Melanoma
        13.4.4    Head & Neck Cancer
        13.4.5    Breast Cancer
        13.4.6    Colorectal Cancer
        13.4.7    Lung Cancer
        13.4.8    Others
    13.5    United States Immunotherapy in Oncology Market (2017-2032) by Route of Administration
        13.5.1    Market Overview
        13.5.2    Oral
        13.5.3    Parenteral
    13.6    United States Immunotherapy in Oncology Market (2017-2032) by End User
        13.6.1    Market Overview
        13.6.2    Hospitals
        13.6.3    Clinics
        13.6.4    Oncology Centers
        13.6.5    Others
14    EU-4 and United  Kingdom Immunotherapy in Oncology Market (2017-2032)
    14.1    EU-4 and United Kingdom Immunotherapy in Oncology Market Historical Value (2017-2023)
    14.2    EU-4 and United Kingdom Immunotherapy in Oncology Market Forecast Value (2024-2032)
    14.3    EU-4 and United Kingdom Immunotherapy in Oncology Market (2017-2032) by Type
        14.3.1    Market Overview
        14.3.2    Monoclonal Antibodies
        14.3.3    Cytokines & Immunomodulators
        14.3.4    Checkpoint Inhibitors
        14.3.5    Others
    14.4    EU-4 and United Kingdom Immunotherapy in Oncology Market (2017-2032) by Indication
        14.4.1    Market Overview
        14.4.2    Prostate Cancer
        14.4.3    Melanoma
        14.4.4    Head & Neck Cancer
        14.4.5    Breast Cancer
        14.4.6    Colorectal Cancer
        14.4.7    Lung Cancer
        14.4.8    Others
    14.5    EU-4 and United Kingdom Immunotherapy in Oncology Market (2017-2032) by Route of Administration
        14.5.1    Market Overview
        14.5.2    Oral
        14.5.3    Parenteral
    14.6    EU-4 and United Kingdom Immunotherapy in Oncology Market (2017-2032) by End User
        14.6.1    Market Overview
        14.6.2    Hospitals
        14.6.3    Clinics
        14.6.4    Oncology Centers
        14.6.5    Others
15    Japan Immunotherapy in Oncology Market
    15.1    Japan Immunotherapy in Oncology Market Historical Value (2017-2023) 
    15.2    Japan Immunotherapy in Oncology Market Forecast Value (2024-2032)
    15.3    Japan Immunotherapy in Oncology Market (2017-2032) by Type
        15.3.1    Market Overview
        15.3.2    Monoclonal Antibodies
        15.3.3    Cytokines & Immunomodulators
        15.3.4    Checkpoint Inhibitors
        15.3.5    Others
    15.4    Japan Immunotherapy in Oncology Market (2017-2032) by Indication
        15.4.1    Market Overview
        15.4.2    Prostate Cancer
        15.4.3    Melanoma
        15.4.4    Head & Neck Cancer
        15.4.5    Breast Cancer
        15.4.6    Colorectal Cancer
        15.4.7    Lung Cancer
        15.4.8    Others
    15.5    Japan Immunotherapy in Oncology Market (2017-2032) by Route of Administration
        15.5.1    Market Overview
        15.5.2    Oral
        15.5.3    Parenteral
    15.6    Japan Immunotherapy in Oncology Market (2017-2032) by End User
        15.6.1    Market Overview
        15.6.2    Hospitals
        15.6.3    Clinics
        15.6.4    Oncology Centers
        15.6.5    Others
16    India Immunotherapy in Oncology Market
    16.1    India Immunotherapy in Oncology Market Historical Value (2017-2023) 
    16.2    India Immunotherapy in Oncology Market Forecast Value (2024-2032)
    16.3    India Immunotherapy in Oncology Market (2017-2032) by Type
        16.3.1    Market Overview
        16.3.2    Monoclonal Antibodies
        16.3.3    Cytokines &Immunomodulators
        16.3.4    Checkpoint Inhibitors
        16.3.5    Others
    16.4    India Immunotherapy in Oncology Market (2017-2032) by Indication
        16.4.1    Market Overview
        16.4.2    Prostate Cancer
        16.4.3    Melanoma
        16.4.4    Head & Neck Cancer
        16.4.5    Breast Cancer
        16.4.6    Colorectal Cancer
        16.4.7    Lung Cancer
        16.4.8    Others
    16.5    India Immunotherapy in Oncology Market (2017-2032) by Route of Administration
        16.5.1    Market Overview
        16.5.2    Oral
        16.5.3    Parenteral
    16.6    India Immunotherapy in Oncology Market (2017-2032) by End User
        16.6.1    Market Overview
        16.6.2    Hospitals
        16.6.3    Clinics
        16.6.4    Oncology Cneters
        16.6.5    Others
17    Regulatory Framework
    17.1    Regulatory Overview
    17.2    US FDA
    17.3    EU EMA
    17.4    INDIA CDSCO
    17.5    JAPAN PMDA
    17.6    Others
18    Patent  Analysis
    18.1     Analysis by Type of Patent
    18.2     Analysis by Publication Year
    18.3     Analysis by Issuing Authority
    18.4     Analysis by Patent Age
    18.5     Analysis by CPC Analysis
    18.6     Analysis by Patent Valuation 
    18.7     Analysis by Key Players
19    Clinical  Trial Analysis
    19.1    Analysis by Trial Registration Year
    19.2    Analysis by Trial Status
    19.3    Analysis by Trial Phase
    19.4    Analysis by Therapeutic Area
    19.5    Analysis by Geography
20    Grant Analysis
    20.1    Analysis by Year
    20.2    Analysis by Amount Awarded
    20.3    Analysis by Issuing Authority
    20.4    Analysis by Grant Product
    20.5    Analysis by Funding Institute
    20.6    Analysis by Departments
    20.7    Analysis by Recipient Organization
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Strategic Initiatives
    22.1     Analysis by Partnership Instances
    22.2     Analysis by Type of Partnership
    22.3     Analysis by Leading Players
    22.4     Analysis by Geography
23    Supplier Landscape
    23.1    Market Share by Top 5 Companies
    23.2    Amgen Inc.
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Company News and Developments
        23.2.5    Certifications 
    23.3    AstraZeneca Plc 
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Company News and Developments
        23.3.5    Certifications
    23.4    F. Hoffmann-La Roche Ltd
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Company News and Developments
        23.4.5    Certifications
    23.5    Bayer AG 
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Company News and Developments
        23.5.5    Certifications
    23.6    Bristol-Myers Squibb Company
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Company News and Developments
        23.6.5    Certifications
    23.7    Eli Lilly and Company
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Company News and Developments
        23.7.5    Certifications
    23.8    Takeda Pharmaceutical Company Limited.
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Company News and Developments
        23.8.5    Certifications
    23.9    Pfizer Inc.
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Company News and Developments
        23.9.5    Certifications
    23.10    Novartis AG
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Company News and Developments
        23.10.5    Certifications
24    Immunotherapy in Oncology Market – Distribution Model (Additional Insight)
    24.1     Overview 
    24.2     Potential Distributors 
    24.3     Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Payment Methods (Additional Insight)

    26.1    Government Funded
    26.2    Private Insurance
    26.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

 

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

 

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

*Additional insights provided are customizable as per client requirements.

*The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

*The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Looking for specific insights?

Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124